Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study

The COVID-19 pandemic, an unprecedented event for current generations of physicians, has stricken hard on society.1 There is a significant lack of effective drugs for stopping viral replication. Lopinavir/ritonavir (LPV/r) is a well-known combination used in patients with HIV which was included in the arsenal against SARS-CoV-2 early in the pandemic.2 Its use in COVID-19 was based on inconsistent results from experimental and clinical research that was mostly done while investigating other β-coronaviruses (SARS and MERS).

Source: Journal of Infection - February 11, 2021 Category: Infectious Diseases Authors: Jaime Lora-Tamayo, Guillermo Maestro, Antonio Lalueza, Manuel Rubio-Rivas, Gracia Villarreal Paul, Francisco Arnalich Fern ández, José Luis Beato Pérez, Juan Antonio Vargas Núñez, Mónica Llorente Barrio, Carlos Lumbreras Bermejo, for the SEMI-COVID- Tags: Letter to the Editor Source Type: research